Core 1: Planning and Evaluation

核心1：规划与评估

• 批准号: 10762163
• 负责人: David K Ann
• 金额: $ 12.42万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-22 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10762163
• 关键词: Award; California; City of Hope Comprehensive Cancer Center; Clinical Trials; Collaborations; Communities; Comprehensive Cancer Center; Contractor; Databases; Education; Educational process of instructing; Educational workshop; Effectiveness; Equity; Evaluation; Feedback; Funding; Future; Goals; Grant; Individual; Joints; Knowledge; Leadership; Measures; Mentors; Mentorship; Modeling; Monitor; Outcome Measure; Performance; Pilot Projects; Play; Process; Program Evaluation; Progress Reports; Publications; Recommendation; Reporting; Research; Research Personnel; Resources; Structure; Surveys; Therapeutic; Training; Training Programs; Training and Education; Translational Research; United States National Institutes of Health; Universities; Work; anticancer research; cancer health disparity; career; career development; drug development; equity, diversity, and inclusion; health disparity; improved; insight; meetings; outreach; programs; success; webinar

The goals of the Planning and Evaluation Core (PEC) are to monitor, evaluate, and assess the progress of our U54 Partnerships in meeting its milestones, objectives, and goals. The Core supports our University of California, Riverside (UCR) – City of Hope Comprehensive Cancer Center (CoHCCC) U54 Partnership’s goals of capacity- building, education, and training. Together in this U54, UCR and CoHCCC aim to develop the collaborations, translational resources, and training programs to enhance diversity in cancer research and achieve equity in drug development - throughout the entire drug development pipeline. To achieve our PEC’s goals we are guided by four boards – the Internal Advisory Board (IAB), External Advisory Board (EAB), Community Advisory Board (CAB), and Diversity, Equity, and Inclusion Board (DEI). Our IAB and EAB have served a key role in guiding our P20 planning grant; in our proposed U54 these two boards will be joined by our newly created CAB and DEI. The inclusion of these two new boards underscores our U54’s commitment to 1) serving the diverse individuals that live in our Southern California communities and 2) to mentor and train a diverse early-stage investigators who are committed to eliminating our current disparities in cancer therapeutics, drug development, and access to clinical trials. Through the activities and oversight of the PEC, our four advisory boards will 1) conduct evaluation, tracking, and reporting of the progress of projects and cores and 2) provide focused feedback to program U54 leadership and investigators. As in our P20 planning grant, the U54 PEC will work with the IAB to provide a structured and rigorous review process to select new Full and Pilot projects as well as Mini-Pilots for the Capacity Core. The PEC will assess all components of our U54 partnership. The PEC will assure that the 1) Research and Evaluation Core training and education programs are effective in providing education and building capacity, 2) Outreach Core works with investigators to be inclusive of the communities we serve, and 3) Capacity Core identifies provides early-stage investigators (ESI) with mentorship in target identification, drug development, and clinical trials. We anticipate that together our Cores will play a key role in developing future U54 projects that build UCR’s capacity in drug development and clinical trials.

规划和评估核心 (PEC) 的目标是监控、评价和评价我们的进展 U54 合作实现其里程碑、目标和目标。核心支持我们的加州大学， Riverside (UCR) – 希望之城综合癌症中心 (CoHCCC) U54 合作伙伴的能力目标- 建设、教育和培训。 UCR 和 CoHCCC 在 U54 中​​共同致力于发展合作， 转化资源和培训计划，以增强癌症研究的多样性并实现公平 药物开发——贯穿整个药物开发流程。为了实现 PEC 的目标，我们的指导方针是 由四个委员会组成：内部顾问委员会 (IAB)、外部顾问委员会 (EAB)、社区顾问委员会 (CAB) 和多元化、公平和包容委员会 (DEI)。我们的 IAB 和 EAB 在指导我们的工作中发挥了关键作用 P20规划补助金；在我们提议的 U54 中​​，我们新创建的 CAB 和 DEI 将加入这两个委员会。 这两个新董事会的加入强调了我们 U54 的承诺：1) 为多元化的个人服务 生活在我们南加州社区的人以及 2) 指导和培训多元化的早期研究人员 他们致力于消除我们目前在癌症治疗、药物开发和获取方面的差距 到临床试验。通过 PEC 的活动和监督，我们的四个顾问委员会将 1) 开展 评估、跟踪和报告项目和核心的进展，2) 提供有针对性的反馈 U54 计划领导层和调查员。正如我们的 P20 规划拨款一样，U54 PEC 将与 IAB 合作， 提供结构化且严格的审查流程来选择新的完整项目和试点项目以及迷你试点项目 能力核心。 PEC 将评估我们 U54 合作伙伴关系的所有组成部分。 PEC 将确保 1) 研究和评估 核心培训和教育计划有效地提供教育和 能力建设，2) Outreach Core 与调查人员合作，包容我们所服务的社区，以及 3) 能力核心识别为早期研究人员 (ESI) 提供目标识别、药物 开发和临床试验。我们预计，我们的核心将在未来的发展中发挥关键作用 U54 项目旨在增强 UCR 的药物开发和临床试验能力。